Effect of low-dose aspirin for skin rash associated with erlotinib therapy in patients with lung cancer.
Kanazawa
Shigenori
S
Yamaguchi
Kazuyuki
K
Kinoshita
Yoshimi
Y
Siomi
Kyouko
K
Tujimoto
Masako
M
Hanayama
Kayoko
K
Sasada
Shinji
S
Hirashima
Tomonori
T
Imamura
Fumio
F
Nomura
Shosaku
S
D000368:Aged; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D000069347:Erlotinib Hydrochloride; D005076:Exanthema / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D015539:Platelet Activation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use; D013929:Thromboxane B2 / Q000097:blood; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D013929:Thromboxane B2; D000069347:Erlotinib Hydrochloride; D001241:Aspirin